A study reveals advances in the understanding and treatment of liver fibrosis, a serious complication in the context of metabolic fatty liver disease, also known as MASLD (metabolic dysfunction-associated steatotic liver disease). This study concludes that activation of the PPAR / -AMPK pathway is an effective strategy to slow the development of liver fibrosis.
